Background: Danone’s Infant Formula Ambitions in China
Danone, the French multinational food company headquartered in Paris, has been one of the most significant foreign players in China’s infant formula market for over two decades. Through its global brands — including Aptamil, Nutrilon, Cow & Gate, and Dumex — Danone built a commanding position in China’s premium infant formula segment, which was valued at approximately USD 25 billion by 2023. At its peak in 2016, Danone commanded an estimated 18% share of China’s premium infant formula market, making China its single largest market for early life nutrition globally.
The company’s China journey, however, has been deeply shaped by regulatory evolution. The 2008 melamine contamination scandal — in which locally produced infant formula tainted with melamine caused the illness of approximately 300,000 infants and the deaths of six — fundamentally restructured China’s dairy industry and regulatory framework. In response, the Chinese government implemented a series of increasingly stringent food safety regulations that culminated in the 2018 infant formula registration system (婴幼儿配方乳粉产品配方注册管理办法), administered by the State Administration for Market Regulation (SAMR).
This case study examines how Danone navigated China’s evolving infant formula regulatory landscape, the strategic decisions that enabled it to maintain market leadership through a period of unprecedented regulatory consolidation, and the lessons this experience offers for foreign food companies operating in China’s most regulated food categories.
China’s Infant Formula Regulatory Regime
China’s infant formula regulatory framework is widely regarded as the strictest in the world. The cornerstone is the 2018 Measures for the Administration of Infant Formula Formula Registration (婴幼儿配方乳粉产品配方注册管理办法), which requires every infant formula product sold in China to undergo pre-market registration with SAMR. The regulation applies to all three stages of infant formula: starter formula (Stage 1, 0-6 months), follow-on formula (Stage 2, 6-12 months), and growing-up milk (Stage 3, 12-36 months).
The key regulatory requirements include several stringent conditions. Each company is limited to a maximum of three formula series with nine product formulations total. Each formula registration application requires a comprehensive technical dossier including full compositional analysis, raw material specifications, manufacturing process validation, stability studies, and clinical evidence of nutritional adequacy. Manufacturing facilities must pass SAMR’s Good Manufacturing Practice (GMP) audits, which include on-site inspections of both domestic and foreign production sites. Labels must comply with GB 10765-2021 (infant formula) and GB 10767-2021 (follow-on and growing-up formula) national food safety standards, with mandatory Chinese-language labeling including detailed nutritional information. The registration certificate is valid for five years, after which re-registration is required.
The 2018 regulation had a dramatic impact on the industry. Of the approximately 2,000 infant formula products on the Chinese market before the regulation, over 1,200 were removed from sale after failing to obtain registration by the 2021 transition deadline. This regulatory consolidation primarily affected smaller domestic brands and foreign companies without the resources to compile comprehensive technical dossiers. The top 10 players, including Danone, saw their combined market share increase from approximately 45% to 65% as the market consolidated around registered products.
The regulatory framework also introduced strict labeling requirements. Products can no longer make implied health claims referencing “closest to breast milk” or suggesting medical benefits. Age-specific claims must be supported by clinical evidence submitted as part of the registration dossier. Cross-border e-commerce (CBEC) channels initially provided a partial loophole for unregistered products, but by 2022, SAMR had extended registration requirements to most CBEC channels, closing this alternative pathway.
The following table summarizes the key stages of China’s infant formula registration process and the regulatory bodies involved at each stage.
| Stage | Duration | Review Body | Key Activities | Outcome |
|---|---|---|---|---|
| 1. Pre-submission consultation | 1-2 months | SAMR Food Evaluation Center | Product classification review, dossier requirements clarification | Written guidance on dossier preparation |
| 2. Sample testing | 2-4 months | CNAS/CMA accredited labs | Full compositional analysis, contaminant testing, stability studies | Testing reports valid for 12 months |
| 3. Dossier submission | 1 month | SAMR online portal | Submission of technical dossier (40-60 documents, 1,000+ pages) | Formal acceptance or rejection |
| 4. Technical review | 4-6 months | SAMR FEC technical committee | Scientific evaluation of composition, safety, nutritional adequacy | Approval or supplemental information request |
| 5. On-site inspection | 1-2 weeks | SAMR inspection team | GMP audit of manufacturing facility (domestic or foreign) | Inspection report (pass/fail) |
| 6. Certificate issuance | 1 month | SAMR | Final approval and certificate registration | Registration certificate (5-year validity) |
Navigating the Registration Process: Danone’s Strategy
Danone’s strategy for navigating China’s infant formula registration system was built on three pillars: local production partnerships, dual-track brand portfolio management, and proactive regulatory engagement.
Local Production Partnerships: Danone invested heavily in local production capacity through strategic partnerships. In 2014, Danone acquired a controlling stake in Yashili (雅士利), a Chinese dairy company based in Guangzhou, for approximately HKD 4.3 billion. This acquisition gave Danone access to Yashili’s existing SAMR-registered production facilities and its distribution network across lower-tier Chinese cities. In 2015, Danone partnered with Mengniu Dairy, China’s largest dairy producer, to form a joint venture that operates production facilities in Inner Mongolia. These partnerships allowed Danone to produce formula locally under Chinese brand names (Dumex, Yashili) while importing premium European-produced brands (Aptamil, Nutrilon) through the registration system.
Dual-Track Brand Portfolio: Danone maintained two parallel product tracks. The imported track featured European-manufactured products (Aptamil from Germany and the Netherlands, Nutrilon from the Netherlands) targeted at premium-segment consumers willing to pay RMB 250-400 per 800g can. These products underwent full SAMR registration as imported formulas, with Danone submitting separate dossiers for each facility and formula variant. The local track featured domestic products manufactured at Yashili’s facilities under the Dumex brand, priced at RMB 150-250 per can, targeting mass-market consumers. This dual-track approach allowed Danone to serve both premium and mass-market segments while diversifying regulatory risk across multiple facilities and registration certificates.
Proactive Regulatory Engagement: Danone established a dedicated China regulatory affairs team of over 50 professionals based in Shanghai and Beijing. The team engaged directly with SAMR during the rule-making process, providing technical feedback on the draft registration measures and participating in industry consultation sessions. Danone also invested in a state-of-the-art testing laboratory in Shanghai that achieved CNAS accreditation, allowing the company to conduct internal pre-submission testing that matched SAMR’s testing protocols. This investment reduced the average dossier preparation time from 12 months to 8 months for Danone’s later applications.
Key Challenges and Mitigation
Despite Danone’s strategic preparation, the 2018 registration system created significant challenges that required ongoing mitigation.
Challenge 1: The Three-Series Nine-Product Cap. The regulation’s limit of three formula series with nine total products per company was particularly challenging for Danone, which had over 40 SKUs across its global portfolio targeting the Chinese market. Danone’s mitigation strategy was to prioritize its highest-volume SKUs for registration — focusing on the Aptamil Profutura (premium), Aptamil Standard (mid-premium), and Dumex (mass-market) series — and to discontinue lower-volume variants. This prioritization was data-driven: products with less than RMB 50 million in annual revenue were discontinued unless they served a strategic positioning role in a key retail chain.
Challenge 2: On-Site GMP Inspections of Foreign Facilities. SAMR conducted on-site GMP inspections at Danone’s production facilities in the Netherlands, Germany, Ireland, and New Zealand. These inspections required months of preparation, including translation of all manufacturing documentation into Chinese, alignment of EU production standards with China’s GMP requirements, and hiring of Mandarin-speaking quality assurance staff at each facility. Danone passed all inspections but the process required an estimated EUR 5-8 million in facility upgrades and audit preparation costs across its European production network.
Challenge 3: Daigou Channel Disruption. The daigou (代购) channel — Chinese overseas personal shoppers who purchased foreign infant formula and shipped it to China — had been a significant sales channel for Danone’s European brands, estimated at 15-20% of China-bound sales. SAMR’s extension of registration requirements to cross-border channels in 2022 effectively shut down the daigou route for unregistered products. Danone mitigated this by accelerating CBEC-specific registration applications and partnering with Tmall Global to create official cross-border storefronts that ensured consumers could still access European products through regulated channels.
Challenge 4: Competition from Domestic Brands. The registration consolidation benefited large domestic players like Feihe (飞鹤) and Yili (伊利), who used their existing registered products to capture market share. Feihe’s market share grew from approximately 8% in 2016 to over 20% by 2023, surpassing Danone as China’s largest infant formula brand by revenue. Danone responded by investing in its local brand portfolio, launching new Dumex products targeted at the premium-mass segment (RMB 180-220 per can) and increasing marketing spend on digital platforms to reach young Chinese mothers.
Lessons for Foreign Food Companies
Danone’s experience navigating China’s infant formula regulations offers several actionable lessons for foreign food companies entering China’s regulated food categories.
- Build Regulatory Capacity Before Market Demand. Danone’s investment in a 50-person China regulatory affairs team and CNAS-accredited testing laboratory was made before the 2018 regulations took effect. Foreign food companies should establish dedicated China regulatory capacity 12-18 months before planned market entry, not after regulatory requirements emerge. The cost of regulatory non-compliance — product bans, market access delays, reputational damage — far exceeds the investment in proactive regulatory infrastructure.
- Local Production Partnerships Reduce Regulatory Risk. Danone’s partnership with Yashili and joint venture with Mengniu provided locally registered production capacity that insulated the company from disruptions to its import supply chain. Foreign food companies in regulated categories should evaluate joint ventures, contract manufacturing, or licensing agreements with Chinese partners who already hold relevant production licenses and registration certificates.
- The Dual-Track Model Provides Strategic Flexibility. By maintaining both imported and locally produced product lines, Danone could serve both premium and mass-market segments while spreading regulatory risk across multiple registration certificates and production facilities. Foreign companies should consider whether a similar dual-track approach — importing premium products while producing mid-market products locally — fits their category and brand portfolio.
- Data-Driven Portfolio Prioritization Is Essential. The three-series nine-product cap forced Danone to make difficult portfolio decisions based on revenue data, margin analysis, and strategic importance. Foreign companies entering regulated Chinese food categories should audit their global portfolio early and identify the 5-10 products most likely to succeed in China, rather than attempting to register their entire catalog.
- Engage Regulators During the Rule-Making Process. Danone’s regulatory affairs team participated in SAMR industry consultations during the drafting of the registration measures. Foreign food companies should establish relationships with relevant Chinese regulators (SAMR, GAC, NHC) and participate in public comment periods for proposed regulations. This engagement provides advance visibility into regulatory changes and opportunities to shape implementation details.
- Plan for Channel Disruption. The closure of the daigou channel demonstrated that alternative distribution channels can be regulated out of existence. Foreign food companies should never build a China market strategy entirely around a regulatory gray area or unofficial channel. Building SAMR-compliant distribution from the start is more costly but ultimately more sustainable.
Where to Go From Here
Danone’s experience in China’s infant formula market demonstrates that even the most stringent regulatory environments can be navigated successfully with strategic preparation, local partnerships, and proactive regulatory engagement. For foreign food companies facing similar regulatory challenges in China, the following resources provide actionable guidance.
- [guide: SLUG-TO-BE-FILLED] — A comprehensive guide to China’s SAMR food product registration process, including dossier templates, testing laboratory directory, and timeline planning tools.
- [comparison: SLUG-TO-BE-FILLED] — A detailed comparison of China’s infant formula registration requirements across imported and domestically produced product pathways.
- [tool: SLUG-TO-BE-FILLED] — An interactive regulatory timeline estimator that calculates expected approval timelines based on product category, testing requirements, and submission timing.
— China Gateway 360 —
Remote China market entry support, built around execution.
